Beijing oncology biotech Avistone raises $140M Series B for commercialization in China, expansion into US
04 Jan 2024
Beijing-based Avistone Biotechnology has raised 1 billion yuan, about $140 million, to bankroll commercialization of its recently approved lung cancer drug in China and run trials of other assets.
SDIC CS Capital and IDG Capital co-led the Series B, disclosed Thursday morning, which also included funding from Yanchuang Capital and Cathay Capital. Also involved is backer Bain Capital, which contributed to the biotech’s $200 million Series A, announced in December 2021 after Avistone had been working for more than half a dozen years under two different entities, as Endpoints News previously reported.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.